Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.720
-0.018 (-2.38%)
At close: Mar 6, 2026, 4:00 PM EST
0.731
+0.010 (1.40%)
After-hours: Mar 6, 2026, 7:32 PM EST
Company Description
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
Skye Bioscience, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Punit Dhillon |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | 858 410 0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer, Principal Accounting Officer and Director |
| Tu Diep M.Sc. | Chief Operating Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 8-K | Current Report |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 16, 2025 | SCHEDULE 13D/A | Filing |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Oct 6, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 10-Q | Quarterly Report |